Literature DB >> 29287025

2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.

Girolamo Crisi1, Silvano Filice2, Maria Michiara3, Pellegrino Crafa4, Silvia Lana1.   

Abstract

OBJECTIVE: The objective of this study was to assess the effective performance of short echo time magnetic resonance spectroscopy (short TE MRS) for 2HG detection as biomarker of isocitrate dehydrogenase (IDH) status in all grade glioma (GL).
METHODS: A total of 82 GL patients were prospectively investigated by short TE MRS at 3.0 T as part of a multimodal magnetic resonance imaging study protocol. Spectral analysis was performed using linear combination model. Tumor specimens were diagnosed as IDH mutant or wild type according to the 2016 World Health Organization (WHO) classification of brain tumors. Spectra were analyzed for the presence of 2HG. The performance of short TE MRS was evaluated in terms of sensitivity, specificity, and positive and negative likelihood ratio on the overall sample and on GL WHO grades II and III and glioblastoma separately.
RESULTS: The specificity and sensitivity estimated on the overall sample were 88% and 77%, respectively. In GL WHO grades II and III, 100% specificity and 75% sensitivity were estimated.
CONCLUSIONS: We reiterate the feasibility to identify IDH status of brain GL using short TE MRS at 3.0 T. The method can correctly detect 2HG as expression of IDH mutation in WHO grades II and III GL with a 100% specificity but a 75% sensitivity. In the evaluation of glioblastoma, short TE MRS performs poorly having a 17% false positive rate.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29287025     DOI: 10.1097/RCT.0000000000000705

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  6 in total

1.  Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.

Authors:  Chong Hyun Suh; Ho Sung Kim; Ji Eun Park; Seung Chai Jung; Choong Gon Choi; Dong-Cheol Woo; Ho Beom Lee; Sang Joon Kim
Journal:  Radiol Imaging Cancer       Date:  2020-07-31

2.  The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Chinmay Sharma; Muhammad Ibrahim; Abhishta Bhandari; Matthew Riggs; Rhondda Jones; Arian Lasocki
Journal:  Neuroradiology       Date:  2021-04-03       Impact factor: 2.804

3.  Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment.

Authors:  Dominik Juskanič; Jana Poláková Mištinová; Samuel Hollý; Monika Sekerešová; Kamil Koleják; Lukáš Pátrovič
Journal:  MAGMA       Date:  2022-01-05       Impact factor: 2.310

Review 4.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

5.  In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Authors:  Valeria Cuccarini; Luigi Antelmi; Bianca Pollo; Rosina Paterra; Chiara Calatozzolo; Anna Nigri; Francesco DiMeco; Marica Eoli; Gaetano Finocchiaro; Greta Brenna; Irene Tramacere; Maria Grazia Bruzzone; Elena Anghileri
Journal:  Neurol Sci       Date:  2019-10-24       Impact factor: 3.307

6.  2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 13.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.